Skip to main content

Outcomes of intravesical chondroitin-sulfate and combined hyaluronic-acid/chondroitin-sulfate therapy on female sexual function in bladder pain syndrome

International Urogynecology Journal volume 30, pages 1857–1862 (2019)Cite this article

Abstract

Introduction and hypothesis

Our aim was to determine the efficacy of intravesical chondroitin sulfate (CS) and combined hyaluronic acid/chondroitin sufate (HA/CS) treatment and their effects on sexual function of females with interstitial cystitis/bladder pain syndrome (IC/BPS).

Methods

A total of 68 female patients with IC/BPS between 2012 and 2018 were reviewed. Thirty-three patients were treated with combined HA/CS and 28 patients were treated with CS. Instillations were performed weekly for the first month, biweekly for the second month, and monthly in the third and fourth months. Before and after the sixth month of the treatment, all patients were evaluated with the Female Sexual Function Index (FSFI), visual analog pain scale (VAS), interstitial cystitis symptom index (ICSI), interstitial cystitis problem index (ICPI), and voiding diary, and changes were recorded.

Results

A statistically significant improvement was determined for FSFI, VAS, ICSI, and ICPI scores after treatment in both groups. Among baseline characteristics, a weak but significant negative correlation was determined only between the ICSI score improvement and age (rho: −0.38; p = 0.03) on statistical analysis. Compared with CS, combined HA/CS treatment was superior in terms of ICSI, ICPI, and daytime and nighttime frequency improvement (0.042, 0.038, 0.039, and 0.045; respectively). All domains of the sexual function index were significantly improved at the sixth month of intravesical therapy in both groups. A statistical difference was not found between the two groups.

Conclusions

Although it seems that intravesical HA/CS combination is superior to CS alone in terms of symptom reduction, both of them have beneficial effects on sexual function.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

References

  1. Bogart LM, Berry SH, Clemens JQ. Symptoms of interstitial cystitis, painful bladder syndrome, and similar diseases in women: a systematic review. J Urol. 2007;177(2):450–6.

    Article  Google Scholar 

  2. van de Merwe JP, Nordling J, Bouchelouche P, Bouchelouche K, Cervigni M, Daha LK, et al. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur Urol. 2008;53(1):60–7.

    Article  Google Scholar 

  3. Meng E, Hsu YC, Chuang YC. Advances in intravesical therapy for bladder pain syndrome (BPS)/interstitial cystitis (IC). Low Urin Tract Symptoms. 2018;10(1):3–11.

    Article  CAS  Google Scholar 

  4. Berry SH, Elliott MN, Suttorp M, Bogart LM, Stoto MA, Eggers P, et al. Prevalence of symptoms of bladder pain syndrome/interstitial cystitis among adult females in the United States. J Urol. 2011;186(2):540–4.

    Article  Google Scholar 

  5. Suskind AM, Berry SH, Ewing BA, Elliott MN, Suttorp MJ, Clemens JQ. The prevalence and overlap of interstitial cystitis/bladder pain syndrome and chronic prostatitis/chronic pelvic pain syndrome in men: results of the RAND interstitial cystitis epidemiology male study. J Urol. 2013;189(1):141–5.

    Article  Google Scholar 

  6. Giannantoni A, Bini V, Dmochowski R, Hanno P, Nickel J, Proietti S, et al. Contemporary management of the painful bladder: a systematic review. Eur Urol. 2012;61(1):29–53.

    Article  Google Scholar 

  7. Lazzeri M, Hurle R, Casale P, Buffi N, Lughezzani G, Fiorini G, et al. Managing chronic bladder diseases with the administration of exogenous glycosaminoglycans: an update on the evidence. Ther Adv Urol. 2016;8(2):91–9.

    Article  CAS  Google Scholar 

  8. Arslan B, Onuk O, Eroglu A, Gezmis CT, Aydin M. Female sexual function following a novel transobturator sling procedure without paraurethral dissection (modified-TOT). Int Braz J Urol. 2017;43(1):142–9.

    Article  Google Scholar 

  9. Gardella B, Porru D, Ferdeghini F, Martinotti E, Nappi RE, Rovereto B, et al. Insight into urogynecologic features of women with interstitial cystitis/painful bladder syndrome. Eur Urol. 2008;54(5):1145–53.

    Article  Google Scholar 

  10. Engeler D, Baranowski AP, Borovicka J, Cottrell AM, Dinis-Oliveira P, Elneil S, et al. EAU guidelines on chronic pelvic pain. In: European Association of Urology guideline. Arnhem, The Netherlands; 2018. p. 1–82.

  11. Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, et al. The female sexual function index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000;26(2):191–208.

    Article  CAS  Google Scholar 

  12. Sirinian E, Azevedo K, Payne CK. Correlation between 2 interstitial cystitis symptom instruments. J Urol. 2005;173(3):835–40.

    Article  Google Scholar 

  13. Hurst RE, Roy JB, Min KW, Veltri RW, Marley G, Patton K, et al. A deficit of chondroitin sulfate proteoglycans on the bladder uroepithelium in interstitial cystitis. Urology. 1996;48(5):817–21.

    Article  CAS  Google Scholar 

  14. Parsons CL, Lilly JD, Stein P. Epithelial dysfunction in nonbacterial cystitis (interstitial cystitis). J Urol. 1991;145(4):732–5.

    Article  CAS  Google Scholar 

  15. Droupy S, Goddard JC. Intravesical glycosaminoglycan therapy—overall conclusions. Urologia. 2017;84(Suppl 1):21.

    Article  Google Scholar 

  16. Steinhoff G, Ittah B, Rowan S. The efficacy of chondroitin sulfate 0.2% in treating interstitial cystitis. Can J Urol. 2002;9(1):1454–8.

    CAS  PubMed  Google Scholar 

  17. Nickel JC, Egerdie B, Downey J, Singh R, Skehan A, Carr L, et al. A real-life multicentre clinical practice study to evaluate the efficacy and safety of intravesical chondroitin sulphate for the treatment of interstitial cystitis. BJU Int. 2009;103(1):56–60.

    Article  Google Scholar 

  18. Gulpinar O, Esen B, Kayıs A, Gokce MI, Suer E. Clinical comparison of intravesical hyaluronic acid and chondroitin sulfate in the treatment of bladder pain syndrome/interstitial cystitis. Neurourol Urodyn. 2018;37(1):257–62.

    Article  Google Scholar 

  19. Porru D, Leva F, Parmigiani A, Barletta D, Choussos D, Gardella B, et al. Impact of intravesical hyaluronic acid and chondroitin sulfate on bladder pain syndrome/interstitial cystitis. Int Urogynecol J. 2012;23(9):1193–9.

    Article  Google Scholar 

  20. Pyo JS, Cho WJ. Systematic review and meta-analysis of intravesical hyaluronic acid and hyaluronic acid/chondroitin sulfate instillation for interstitial cystitis/painful bladder syndrome. Cell Physiol Biochem. 2016;39(4):1618–25.

    Article  CAS  Google Scholar 

  21. Cervign M, Natale F, Nasta L, Mako A. Intravesical hyaluronic acid and chondroitin sulphate for bladder pain syndrome/interstitial cystitis: long-term treatment results. Int Urogynecol J. 2012;23(9):1187–92.

    Article  Google Scholar 

  22. Gardella B, Porru D, Nappi RE, Dacco MD, Chiesa A, Spinillo A. Interstitial cystitis is associated with vulvodynia and sexual dysfunction—a case control study. J Sex Med. 2011;8(6):1726–34.

    Article  Google Scholar 

  23. Ottem DP, Carr LK, Perks AE, Lee P, Teichman JM. Interstitial cystitis and female sexual dysfunction. Urology. 2007;69(4):608–10.

    Article  Google Scholar 

  24. Hung MJ, Su TH, Lin YH, Huang WC, LiN TY, Hsu CS, et al. Changes in sexual function of women with refractory intertitial cystitis/bladder pain syndrome after intravesical therapy with a hyaluronic acid solution. J Sex Med. 2014;11(9):2256–63.

    Article  CAS  Google Scholar 

  25. Nickel JC, Parsons CL, Forrest J, Kaufman D, Evans R, Chen A, et al. Improvement in sexual functioning in patients with interstitial cystitis/painful bladder syndrome. J Sex Med. 2008;5(2):394–9.

    Article  Google Scholar 

  26. Wiegel M, Meston C, Rosen R. The female sexual function index (FSFI): cross-validation and development of clinical cutoff scores. J Sex Marital Ther. 2005;31(1):1–20.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Istanbul Gaziosmanpasa Taksim Training and Research Hospital, Karayolları Str. No:621 Gaziosmanpaşa, Istanbul, Turkey

    Burak Arslan, Serkan Gönültaş, Ersin Gökmen, Oktay Özman, Mustafa Asım Avci & Enver Özdemir

Authors
  1. Burak Arslan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Serkan Gönültaş
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ersin Gökmen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Oktay Özman
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mustafa Asım Avci
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Enver Özdemir
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Burak Arslan.

Ethics declarations

Conflicts of interest

None.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Arslan, B., Gönültaş, S., Gökmen, E. et al. Outcomes of intravesical chondroitin-sulfate and combined hyaluronic-acid/chondroitin-sulfate therapy on female sexual function in bladder pain syndrome. Int Urogynecol J 30, 1857–1862 (2019). https://doi.org/10.1007/s00192-019-04036-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00192-019-04036-2

Keywords

  • Interstitial cystitis
  • Sexual function
  • Chondroitin sulfate
  • Hyaluronic acid